Read the full stored bill text
89(R) HB 4014 - Engrossed version - Bill Text
By: Bucy, Oliverson, Pierson, Romero, et al.
H.B. No. 4014
A BILL TO BE ENTITLED
AN ACT
relating to a study on the use of psychedelic therapies in the
treatment of certain conditions.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
SECTION 1. (a) In this Act:
(1) "Commission" means the Health and Human Services
Commission.
(2) "Psychedelic therapies" means the use of
3,4-methylenedioxymethamphetamine (MDMA), psilocybin, or ketamine
to treat mental health or other medical conditions.
(b) The commission, in consultation with Baylor College of
Medicine and the Center for Psychedelic Research and Therapy at
Dell Medical School at The University of Texas at Austin, shall
conduct a study on the use of psychedelic therapies for treatment of
post-traumatic stress disorder, depression, and other co-occurring
conditions.
(c) In conducting the study, the commission shall:
(1) review clinical trials on the efficacy of using
psychedelic therapies in the treatment of post-traumatic stress
disorder, depression, and other co-occurring conditions;
(2) review current literature regarding the use of
psychedelic therapies in the treatment of post-traumatic stress
disorder, depression, and other co-occurring conditions;
(3) review actions of the United States Food and Drug
Administration regarding psychedelic therapies for treatment of
post-traumatic stress disorder, depression, and other co-occurring
conditions;
(4) evaluate treatment guidelines for use of
psychedelic therapies to treat post-traumatic stress disorder,
depression, and other co-occurring conditions and recommend
guidelines and best practices for providers; and
(5) evaluate patient access to current treatment for
post-traumatic stress disorder, depression, and other co-occurring
conditions and recommend legislative or other actions necessary to
ensure patient access to psychedelic therapies following approval
by the United States Food and Drug Administration, including
considerations of provider availability, affordability,
accessibility, training and licensure, and other regulatory
requirements.
(d) In addition to any money appropriated by the
legislature, the commission may solicit and accept federal funds
and gifts, grants, or donations from any source to administer and
finance the study conducted under this section.
(e) Not later than December 1, 2026, the commission shall
submit to the governor, the lieutenant governor, the speaker of the
house of representatives, and the chair of the standing committee
of each house of the legislature with primary jurisdiction over the
commission a written report that includes:
(1) the results of the study conducted under this
section; and
(2) any recommendations for legislative or other
action necessary to ensure patient access to psychedelic therapies
for treatment of post-traumatic stress disorder, depression, and
other co-occurring conditions after those therapies are approved by
the United States Food and Drug Administration.
(f) This Act expires September 1, 2027.
SECTION 2. The Health and Human Services Commission is
required to implement a provision of this Act only if the
legislature appropriates money specifically for that purpose. If
the legislature does not appropriate money specifically for that
purpose, the commission may, but is not required to, implement a
provision of this Act using other money available for that purpose.
SECTION 3. This Act takes effect September 1, 2025.